Baines Ivan C, Colas Pierre
Aptanomics, 181-203 avenue Jean Jaurès, 69007 Lyon, France.
Drug Discov Today. 2006 Apr;11(7-8):334-41. doi: 10.1016/j.drudis.2006.02.007.
Peptide aptamers are combinatorial protein reagents that bind to target proteins with a high specificity and a strong affinity. By so doing, they can modulate the function of their cognate targets. Because peptide aptamers introduce perturbations that are similar to those caused by therapeutic molecules, their use identifies and/or validates therapeutic targets with a higher confidence level than is typically provided by methods that act upon protein expression levels. The unbiased combinatorial nature of peptide aptamers enables them to 'decorate' numerous polymorphic protein surfaces, whose biological relevance can be inferred through characterization of the peptide aptamers. Bioactive aptamers that bind druggable surfaces can be used in displacement screening assays to identify small-molecule hits to the surfaces. The peptide aptamer technology has a positive impact on drug discovery by addressing major causes of failure and by offering a seamless, cost-effective process from target validation to hit identification.
肽适配体是一类组合蛋白试剂,它们能以高特异性和强亲和力结合靶蛋白。通过这样做,它们可以调节其同源靶标的功能。由于肽适配体引入的干扰与治疗分子引起的干扰相似,因此与作用于蛋白质表达水平的方法相比,它们的使用能够以更高的置信度识别和/或验证治疗靶点。肽适配体无偏向性的组合性质使它们能够“修饰”众多多态性蛋白质表面,通过对肽适配体的表征可以推断其生物学相关性。结合可成药表面的生物活性适配体可用于置换筛选试验,以识别作用于这些表面的小分子命中物。肽适配体技术通过解决主要的失败原因,并提供从靶点验证到命中物识别的无缝、经济高效的流程,对药物发现产生了积极影响。